Back

High SAMe-TT2R2 score, labile INR and major adverse outcomes in a real life cohort of anticoagulated patients with non-valvular atrial fibrillation

28 August 2016 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Anticoagulation in atrial fibrillation III Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Diego Iglesias

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)

24 More presentations in this session

Presentation thumbnail
Professor D. Xavier (Bangalore, IN)
Abstract Slides
Presentation thumbnail
Doctor C. Gatti (Ravenna, IT)
Abstract Slides
Presentation thumbnail
Doctor J. Wieczorek (Katowice, PL)
Abstract Slides
Presentation thumbnail
Associate Professor A. Parwani (Berlin, DE)
Presentation thumbnail
Doctor P. Chan (London, GB)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3 - Anticoagulation in atrial fibrillation III

The Event

Event poster

ESC Congress 2016

28 August 2016 14:00 CET
You may be interested in
thumbnail
Webinar
ACVC Biomarker Talk Series - Biomarkers in atrial fibrillation
24 November 2021
thumbnail
Congress Presentation
Adherence and treatment satisfaction among atrial fibrillation patients treated with VKAs versus NOACs: real-world data from a single-center cohort
12 April 2026
thumbnail
Congress Presentation
Impact of clopidogrel metabolizer status on platelet aggregation and association with outcomes in AF patients undergoing PCI
30 August 2025
thumbnail
Congress Presentation
Clinical and prognosis assessment of Atrial Fibrillation patients with significant valvular disease. Validation of the EHRA valve classification (Evaluated Heartvalves. Rheumatic or Artificial)
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources